Literature DB >> 15018131

SARS: ventilatory and intensive care.

Loretta Y C Yam1, Rong Chang Chen, Nan Shan Zhong.   

Abstract

Severe acute respiratory syndrome (SARS) is an emerging infection caused by a novel coronavirus. It is characterised by a highly infectious syndrome of fever and respiratory symptoms, and is usually associated with bilateral lung infiltrates. The clinical syndrome of SARS often progresses to varying degrees of respiratory failure, with about 20% of patients requiring intensive care. Despite concern about potential aerosol generation, non-invasive ventilation (NIV) has been reported to be efficacious in the treatment of SARS-related ARF without posing infection risks to health care workers (HCW). Spontaneous pneumomediastinum and pneumothorax in SARS is common. The incidence of NIV-associated barotrauma ranged from 6.6% to 15%. Patients who fail to tolerate NIV or fail NIV with progressive dyspnoea, tachypnoea and hypoxaemia should be intubated and mechanically ventilated. Mortality rates in intensive care units for SARS patients were high: 34-53% at 28 days, when some patients were still being ventilated. Strict adherence to infection control measures including isolation, use of appropriate personal protective equipment and negative pressure environment had been reported to eliminate cross-infection to HCW.

Entities:  

Mesh:

Year:  2003        PMID: 15018131      PMCID: PMC7169203          DOI: 10.1046/j.1440-1843.2003.00521.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


INTRODUCTION

The initial fever and respiratory symptoms of severe acute respiratory syndrome (SARS) often progress rapidly to acute respiratory failure (ARF) with varying levels of severity. Reported rates of intensive care (ICU) admission vary between 19 to 32%. , , , , , Early ARF usually peaks by 8 days after symptom onset. , But can be delayed with a protracted course. In the ICU, mortality rates similar to or lower than those reported for the acute respiratory distress syndrome (ARDS) have been reported. , The following recommendations on the ventilatory and ICU management of SARS are based on published data as well as our local experience.

INDICATIONS FOR ICU CARE

Patients who meet the criteria for acute respiratory distress syndrome (ARDS, defined by PaO2/FiO2≤ 200 mmHg) should be cared for in an ICU. Depending on availability, observation in a high dependency (HDU) setting or ICU is indicated in those who meet the criteria for acute lung injury ((ALI), defined by PaO2/FiO2 > 200–300 mmHg, or in those who presented with tachypnoea (respiratory rate > 30/min) and more than 50% progression of chest (bilateral or multilobular) shadows within 48 hours.) Patients who develop signs of sepsis, septic shock or multiorgan failure. As SARS is characteristically accompanied by single organ (respiratory) failure multiorgan failure is usually a result of superimposed hospital‐acquired bacterial infection.

MANAGEMENT OF RESPIRATORY FAILURE

Pharmacological agents

There is no specific treatment currently available for SARS. Empirical therapy includes broad‐spectrum antibiotics and various antiviral agents, with no proven efficacy. , , , , Based on the hypothesis that the respiratory failure of SARS is secondary to an immunopathological phenomenon, anti‐inflammatory agents like corticosteriods have been widely used in Canada, China , , , and Hong Kong. , , , In particular, short‐term intravenous high dose (pulsed) methylprednisolone (500–1000 mg) has been advocated to treat progressive pulmonary infiltrates and hypoxaemia , , with good response reported. , , , Half of the critically ill patients with SARS might benefit from initial intravenous corticosteroid. Interferon and immunoglobin (including Pentaglobin) , , have also been used.

Oxygen supplementation

Oxygen was required in 50–85% of SARS patients , , and may be delivered via nasal cannulae at 1–6 L per minute (LPM) or via non‐rebreathing masks (NRM) at 8–15 LPM. Patients with continuing deterioration of respiratory status will require ICU care.

Ventilatory care

Non‐invasive ventilation

Non‐invasive ventilation (NIV) is a standard mode of ventilatory assist in early ARF and ARDS due to various causes. , While mortality benefit was not shown, NIV could reduce intubation rate and thus the complications associated with intubation and mechanical ventilation. This may be of particular advantage in SARS, where anti‐inflammatory agents could predispose the patients to ventilator‐associated pneumonia (VAP). Despite concern about potential aerosol generation, NIV has been reported to be effective in the treatment of SARS‐related ARF without posing infection risks to HCWs. , , , A study reported that NIV was indicated in ALI and early ARDS when desaturation (SaO2 < 93%) occurred despite oxygen supplementation (> 3–5 L/m), with persistent tachypnoea (≥ 30/min) and progressive deterioration on CXR. Intubation could be avoided in up to two‐thirds of cases in a Hong Kong series (unpubl. data, 2003) and in two studies from Guangzhou. , The usual contraindications to NIV apply, including disturbed consciousness, uncooperative patient, high aspiration risk and haemodynamic instability. Conventional mechanical ventilators (pressure support mode), BiPAP® or continuous positive airway pressure (CPAP) machines, preferably with leak compensation capability, may be used to deliver NIV. SARS‐related ARF responds readily to low positive pressures of CPAP 4–10 cm H2O or inspiratory pressures (IPAP) of < 10 cm H2O and expiratory pressures (EPAP) of 4–6 cm water. Higher pressures should be avoided because of the common finding of spontaneous pneumomediastinum and pneumothorax in SARS. The incidence of NIV‐associated barotrauma ranged from 6.6% to 15% (unpubl. data, 2003). To reduce aerosol generation, exhalation ports that generate round‐the‐tube airflow (e.g. Whisper‐Swivel II, (Respironics, Murrysville, Pennsylvania, USA)) are preferred to those producing jet outflow. A viral‐bacterial filter interposed between the mask and the exhalation port could further reduce environmental contamination. Strict adherence to infection control measures including isolation, use of appropriate personal protective equipment (PPE) and negative pressure environment had been reported to eliminate cross‐infection to healthcare workers. Further details on infection control are shown in Table 1.
Table 1

Infection control precautions in the ICU , ,

Staff education
 High risk procedures, alternatives, and precautions
 Limit opportunities for exposure: Limit aerosol generating procedures & limit number of HCWs present
 Effective use of time during patient contact
 How to ‘gown’ and ‘degown’ without contamination
 Emphasis on importance of vigilance and adherence to all infection control precautions
 Emphasis on importance of monitoring own health
 Dissemination of information on SARS and other prevailing infections as they evolve
Personal protection equipment (PPE)
N95 respirator/surgical mask for airborne/droplet precautions
 Contact precautions: Disposable gloves, gown, cap
 Eye protection with non‐reusable goggles and face‐shield
 Powered air purification respirators (PAPR) may be used when performing high‐risk procedures (1, 2)
 Pens, paper, other personal items and medical records should not be allowed into or removed from the room
 Immediate removal of grossly contaminated PPE and showering in nearby facility
Environment/Equipment
 Conform to CDC recommendations for environmental control of tuberculosis: Minimum 6 air change per hour (ACH). Where feasible, increase to 3 12 ACH or recirculate air through HEPA filter
 Preferred: Negative pressure isolation rooms with antechambers, with doors closed at all times
 Equipment should not be shared among patients
 Alcohol‐based hand and equipment disinfectants
 Gloves, gowns, masks and disposal units should be readily available
 Careful and frequent cleaning of surfaces with disposable cloths and alcohol‐based detergents
 Use of video camera equipment or windows to monitor patients
Transport
 Avoid patient transport where possible: Balance risks and benefits of investigations which necessitate patient transport
Special precautions for ICU
 Viral/bacterial filter placed in expiratory port of bag‐valve mask
 Two filters per ventilator: Between expiratory port and the ventilator, and another on the exhalation outlet of the ventilator
 Closed‐system in‐line suctioning of endotracheal/tracheostomy tubes (Fig. 2a)
 Heat and moisture exchanger (HME) preferred to heated humidifier: Careful handling of contaminated HME required (Fig. 2a)
Scavenger system for exhalation port of ventilator (e.g. Servo Evac 180, Fig. 2b): Optional if negative pressure with high air change (>12/h) is achieved
Preoxygenate patient and temporarily switch off machine when ventilator circuit disconnection required (e.g. change of ventilator tubings, HME, etc.)
Infection control precautions in the ICU , , Powered air purifying respirator (PAPR) (Air‐mate). (a) Frontal view. (b) Back view of battery with HEPA filter and duct supplying purified air to hood unit. (a) Closed circuit (in‐line) suction system with heat and moisture exchanger (HME) shown as white flexitube connected to a viral/bacterial filter. (b) Servo‐Evac 180 for connection to exhalation port of ventilator. The Servo‐Evac 180 consists of a connection to the ventilator's expiratory port (curved flexitube) which empties expired air into a Evac Bag, which has a one‐way valve through which expired gas can be removed via an evacuation hose (white tube) connected to a suction source. The straight flexitube is open to the atmosphere to ensure the patient is not subjected to undue negative pressure or excessive resistance in case the suction sources is interrupted.

Mechanical ventilation (MV)

Patients who fail to tolerate NIV or fail NIV with progressive dyspnoea, tachypnoea and hypoxaemia should be intubated and mechanically ventilated. , Similar indications apply if NIV had not been used prior to intubation. Both pressure and volume control ventilation have been used to treat SARS‐related ARF. Care should be taken to keep the tidal volume low at 5–6 mL/kg, and alveolar (plateau) pressures below 30 cm H2O. PEEP levels should be titrated to as low as possible to maintain appropriate oxygenation. Since physical activity or even coughing may result in severe desaturation, sufficient sedation during early mechanical ventilation is useful to eliminate anxiety, thus improving pulmonary oxygenation. A high rate of barotrauma (34%) had been reported, again highlighting the need to avoid excessive volumes and pressures. Permissive hypercapnia resulting from cautious ventilator management necessitated short‐term neuromuscular blockade in 52–70% of ventilated cases. , Other ventilator modes used include airway pressure release ventilation and high frequency oscillatory ventilation but results have not been reported. Apart from barotrauma, common complications of mechanical ventilation include ventilator‐associated pneumonia, acute renal failure, deep vein thrombosis and pulmonary embolism. Low baseline PaO2/FiO2 ratios and high APACHE II scores were the only predictors for protracted ARDS and death in one study. ICU mortality rates were high: 34–53% at 28 days, when some patients were still being ventilated. , To improve survival, research is required to identify early all SARS patients who may progress to severe ARDS and to develop effective treatment. Meticulous infection control measures (Table 1) are mandatory in the care of ventilated SARS patients in ICU, where HCW are exposed to high risk procedures like bag‐mask ventilation, NIV, endotracheal intubation, actual or potential circuit disconnections, suctioning, tracheostomy and bronchoscopy with or without bronchoalveolar lavage. The duration of manual ventilation during resuscitation procedures should be reduced to a minimum. Endotracheal intubation should be performed by the most skilled person available using rapid sequence induction: risk of aerosol generation is lowest when the patient is paralysed. All special precautions for ICU patients must be complied with. Contrary to recommendations to avoid NIV and nebulised therapy, NIV has not been reported to be associated with increased infection risk for HCW, and doubts have been raised about the role of nebulised treatment on the spread of SARS within the hospital. On the other hand, it is always prudent to limit opportunities for HCW exposure and to perform aerosol generating procedures in an airborne isolation environment. In addition to ensuring the safety of HCWs, timely psychological support is critical to maintain staff morale. The above strategies had been effective in preventing infection in ICU HCWs in hospitals in Singapore and Hong Kong, and in the latter case over 80 HCWs exposed to NIV and mechanical ventilation of SARS patients were proved to be serologically negative for SARS‐CoV after the outbreak (unpubl. data, 2003).
  16 in total

1.  Non-invasive ventilation in acute respiratory failure.

Authors: 
Journal:  Thorax       Date:  2002-03       Impact factor: 9.139

2.  Noninvasive ventilation in acute respiratory failure--a meta-analysis update.

Authors:  John V Peter; John L Moran; Jennie Phillips-Hughes; David Warn
Journal:  Crit Care Med       Date:  2002-03       Impact factor: 7.598

3.  Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.

Authors:  Christopher M Booth; Larissa M Matukas; George A Tomlinson; Anita R Rachlis; David B Rose; Hy A Dwosh; Sharon L Walmsley; Tony Mazzulli; Monica Avendano; Peter Derkach; Issa E Ephtimios; Ian Kitai; Barbara D Mederski; Steven B Shadowitz; Wayne L Gold; Laura A Hawryluck; Elizabeth Rea; Jordan S Chenkin; David W Cescon; Susan M Poutanen; Allan S Detsky
Journal:  JAMA       Date:  2003-05-06       Impact factor: 56.272

4.  Critically ill patients with severe acute respiratory syndrome.

Authors:  Robert A Fowler; Stephen E Lapinsky; David Hallett; Allan S Detsky; William J Sibbald; Arthur S Slutsky; Thomas E Stewart
Journal:  JAMA       Date:  2003-07-16       Impact factor: 56.272

5.  Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China.

Authors:  Z Zhao; F Zhang; M Xu; K Huang; W Zhong; W Cai; Z Yin; S Huang; Z Deng; M Wei; J Xiong; P M Hawkey
Journal:  J Med Microbiol       Date:  2003-08       Impact factor: 2.472

6.  Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome.

Authors:  Thomas W K Lew; Tong-Kiat Kwek; Dessmon Tai; Arul Earnest; Shi Loo; Kulgit Singh; Kim Meng Kwan; Yeow Chan; Chik Foo Yim; Siam Lee Bek; Ai Ching Kor; Wee See Yap; Y Rubuen Chelliah; Yeow Choy Lai; Soon-Keng Goh
Journal:  JAMA       Date:  2003-07-16       Impact factor: 56.272

7.  A retrospective study of 78 patients with severe acute respiratory syndrome.

Authors:  Zhenglun Xiao; Yimin Li; Rongchang Chen; Shiyue Li; Shuqing Zhong; Nanshan Zhong
Journal:  Chin Med J (Engl)       Date:  2003-06       Impact factor: 2.628

8.  A hospital outbreak of severe acute respiratory syndrome in Guangzhou, China.

Authors:  Wei Wu; Jingfeng Wang; Pinming Liu; Weixian Chen; Songmei Yin; Shanping Jiang; Li Yan; Jun Zhan; Xilong Chen; Jianguo Li; Zitong Huang; Hongzhang Huang
Journal:  Chin Med J (Engl)       Date:  2003-06       Impact factor: 2.628

9.  Development of a standard treatment protocol for severe acute respiratory syndrome.

Authors:  Loletta K-Y So; Arthur C W Lau; Loretta Y C Yam; Thomas M T Cheung; Edwin Poon; Raymond W H Yung; K Y Yuen
Journal:  Lancet       Date:  2003-05-10       Impact factor: 79.321

10.  ICU management of severe acute respiratory syndrome.

Authors:  Stephen E Lapinsky; Laura Hawryluck
Journal:  Intensive Care Med       Date:  2003-05-09       Impact factor: 17.440

View more
  21 in total

1.  Management of Critically Ill Patients with Severe Acute Respiratory Syndrome (SARS).

Authors:  Arthur Chun-Wing Lau; Loretta Yin-Chun Yam; Loletta Kit-Ying So
Journal:  Int J Med Sci       Date:  2004-03-10       Impact factor: 3.738

Review 2.  Treatment of severe acute respiratory syndrome.

Authors:  S T Lai
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-09       Impact factor: 3.267

Review 3.  COVID-19: Immunology and treatment options.

Authors:  Susanna Felsenstein; Jenny A Herbert; Paul S McNamara; Christian M Hedrich
Journal:  Clin Immunol       Date:  2020-04-27       Impact factor: 3.969

4.  Correlation between continuous Positive end-expiratory pressure (PEEP) values and occurrence of Pneumothorax and Pneumomediastinum in SARS-CoV2 patients during non-invasive ventilation with Helmet.

Authors:  Antonio Gidaro; Federica Samartin; Anna Maria Brambilla; Chiara Cogliati; Stella Ingrassia; Francesco Banfi; Viola Cupiraggi; Cecilia Bonino; Marco Schiuma; Andrea Giacomelli; Stefano Rusconi; Jaqueline Currà; Antonio Luca Brucato; Emanuele Salvi
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2021-06-28       Impact factor: 0.670

5.  Bleeding in COVID-19 severe pneumonia: The other side of abnormal coagulation pattern?

Authors:  Clara Benedetta Conti; Sonia Henchi; Giovanni Paolo Coppeta; Sophie Testa; Roberto Grassia
Journal:  Eur J Intern Med       Date:  2020-05-07       Impact factor: 4.487

Review 6.  Preparing your intensive care unit for the COVID-19 pandemic: practical considerations and strategies.

Authors:  Ken Junyang Goh; Jolin Wong; Jong-Chie Claudia Tien; Shin Yi Ng; Sewa Duu Wen; Ghee Chee Phua; Carrie Kah-Lai Leong
Journal:  Crit Care       Date:  2020-05-11       Impact factor: 9.097

7.  Approaching Otolaryngology Patients During the COVID-19 Pandemic.

Authors:  Chong Cui; Qi Yao; Di Zhang; Yu Zhao; Kun Zhang; Eric Nisenbaum; Pengyu Cao; Keqing Zhao; Xiaolong Huang; Dewen Leng; Chunhan Liu; Ning Li; Yan Luo; Bing Chen; Roy Casiano; Donald Weed; Zoukaa Sargi; Fred Telischi; Hongzhou Lu; James C Denneny; Yilai Shu; Xuezhong Liu
Journal:  Otolaryngol Head Neck Surg       Date:  2020-05-12       Impact factor: 3.497

8.  Emergency tracheal intubation in 202 patients with COVID-19 in Wuhan, China: lessons learnt and international expert recommendations.

Authors:  Wenlong Yao; Tingting Wang; Bailin Jiang; Feng Gao; Li Wang; Hongbo Zheng; Weimin Xiao; Shanglong Yao; Wei Mei; Xiangdong Chen; Ailin Luo; Liang Sun; Tim Cook; Elizabeth Behringer; Johannes M Huitink; David T Wong; Meghan Lane-Fall; Alistair F McNarry; Barry McGuire; Andrew Higgs; Amit Shah; Anil Patel; Mingzhang Zuo; Wuhua Ma; Zhanggang Xue; Li-Ming Zhang; Wenxian Li; Yong Wang; Carin Hagberg; Ellen P O'Sullivan; Lee A Fleisher; Huafeng Wei
Journal:  Br J Anaesth       Date:  2020-04-10       Impact factor: 11.719

9.  Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19).

Authors:  Waleed Alhazzani; Morten Hylander Møller; Yaseen M Arabi; Mark Loeb; Michelle Ng Gong; Eddy Fan; Simon Oczkowski; Mitchell M Levy; Lennie Derde; Amy Dzierba; Bin Du; Michael Aboodi; Hannah Wunsch; Maurizio Cecconi; Younsuck Koh; Daniel S Chertow; Kathryn Maitland; Fayez Alshamsi; Emilie Belley-Cote; Massimiliano Greco; Matthew Laundy; Jill S Morgan; Jozef Kesecioglu; Allison McGeer; Leonard Mermel; Manoj J Mammen; Paul E Alexander; Amy Arrington; John E Centofanti; Giuseppe Citerio; Bandar Baw; Ziad A Memish; Naomi Hammond; Frederick G Hayden; Laura Evans; Andrew Rhodes
Journal:  Intensive Care Med       Date:  2020-03-28       Impact factor: 17.440

10.  Infection control in the management of highly pathogenic infectious diseases: consensus of the European Network of Infectious Disease.

Authors:  Philippe Brouqui; Vincenzo Puro; Francesco M Fusco; Barbara Bannister; Stephan Schilling; Per Follin; René Gottschalk; Robert Hemmer; Helena C Maltezou; Kristi Ott; Renaat Peleman; Christian Perronne; Gerard Sheehan; Heli Siikamäki; Peter Skinhoj; Giuseppe Ippolito
Journal:  Lancet Infect Dis       Date:  2009-05       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.